Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | H1299 cell lysate vaccine + Montanide ISA 51 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| H1299 cell lysate vaccine | H1299 cell lysate vaccine comprises cell lysate obtained from the lung tumor cell line H1299, which potentially induces immunity against cancer-testis antigens (CTAs) and increases anti-tumor immune response (PMID: 34430349). | |||
| Montanide ISA 51 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05642195 | Phase Ib/II | H1299 cell lysate vaccine + Montanide ISA 51 + Nogapendekin alfa inbakicept H1299 cell lysate vaccine + Montanide ISA 51 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer | Suspended | USA | 0 |